Nov 14, 2025 · Dosage Recommendations for Concomitant Use with Moderate or Strong CYP3A4 Inhibitors The recommended CAPLYTA dosage in patients who receive: Strong CYP3A4 inhibitors is …

Jul 14, 2025 · Kerendia is used for the treatment of patients with chronic kidney disease (CKD) associated with type 2 diabetes and heart failure. Includes Kerendia side effects, interactions, and …

Dec 10, 2025 · Weak CYP3A4 Inducers: Clinically important effects on rimegepant exposure not expected. P-gp and BCRP Inhibitors BCRP inhibitors: Clinically important effects on rimegepant …

Nov 19, 2025 · Zopiclone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zopiclone. Management: If coadministered with strong CYP3A4 inhibitors, initiate zopiclone at 3.75 …

Jun 10, 2025 · Moderate CYP3A4 inhibitors: If used concomitantly with a moderate CYP3A4 inhibitor, recommended dosage is a 50-mg dose initially; avoid taking a second dose within 24 hours of initial …

Dec 18, 2025 · Detailed dosage guidelines and administration information for Vraylar (cariprazine). Includes dose adjustments, warnings and precautions.

Apr 23, 2025 · CYP3A4 inhibitors and inducers Ubrelvy, Nurtec ODT and Qulipta interact with this group of medications, so you may need to change your migraine medication dose or not take the migraine …

Sep 1, 2025 · Detailed dosage guidelines and administration information for Qulipta (atogepant). Includes dose adjustments, warnings and precautions.

Jan 21, 2025 · Moderate or strong CYP3A4 inhibitors: Potential increased systemic exposure to lumateperone and increased risk of adverse effects. Reduce dosage of lumateperone. Weak CYP3A …

Oct 1, 2025 · Detailed dosage guidelines and administration information for Ingrezza (valbenazine). Includes dose adjustments, warnings and precautions.